(Q40758392)

English

Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy

scientific article published on 11 May 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 September 2017

Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy (English)

1 reference

Europe PubMed Central

23 September 2017

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

9

object named as

Ulrich Germing

1 reference

Europe PubMed Central

23 September 2017

author name string

Aleksandar Radujkovic

1

1 reference

Europe PubMed Central

23 September 2017

Sascha Dietrich

2

1 reference

Europe PubMed Central

23 September 2017

Mindaugas Andrulis

3

1 reference

Europe PubMed Central

23 September 2017

Axel Benner

4

1 reference

Europe PubMed Central

23 September 2017

Thomas Longerich

5

1 reference

Europe PubMed Central

23 September 2017

Andrea Pellagatti

6

1 reference

Europe PubMed Central

23 September 2017

Kriti Nanda

7

1 reference

Europe PubMed Central

23 September 2017

Thomas Giese

8

1 reference

Europe PubMed Central

23 September 2017

Stefan Baldus

10

1 reference

Europe PubMed Central

23 September 2017

Jacqueline Boultwood

11

1 reference

Europe PubMed Central

23 September 2017

Anthony D Ho

12

1 reference

Europe PubMed Central

23 September 2017

Peter Dreger

13

1 reference

Europe PubMed Central

23 September 2017

Thomas Luft

14

1 reference

Europe PubMed Central

23 September 2017

language of work or name

0 references

publication date

11 May 2016

1 reference

Europe PubMed Central

23 September 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

23 September 2017

139

1 reference

Europe PubMed Central

23 September 2017

6

1 reference

Europe PubMed Central

23 September 2017

1402-1413

1 reference

Europe PubMed Central

23 September 2017

Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Revised international prognostic scoring system for myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Drug therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

The clinical pharmacology of antineoplastic agents (first of two parts).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Breaking the cell cycle of HSCs by p57 and friends

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Leukemia stem cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Jetset: selecting the optimal microarray probe set to represent a gene

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

A global test for groups of genes: testing association with a clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Current therapy of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Cancer stem cells: relevance to SCT

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Independent and functional validation of a multi-tumour-type proliferation signature

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

TGF-beta signaling by Smad proteins

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

TGFβ restores hematopoietic homeostasis after myelosuppressive chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Smad4 is critical for self-renewal of hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Primacy of resistance rather than toxicity in determining outcome of therapy for AML.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

p57 Is Required for Quiescence and Maintenance of Adult Hematopoietic Stem Cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Awakening dormant haematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30181

21 January 2018

Identifiers

10.1002/IJC.30181

1 reference

Europe PubMed Central

23 September 2017

1 reference

Europe PubMed Central

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40758392&oldid=1906730006"